Cargando…
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials
OBJECTIVES: Typically, prognostic capability of gene expression profiling (GEP) is studied in the context of clinical trials, for which 50%‐80% of patients are not eligible, possibly limiting the generalizability of findings to routine practice. Here, we evaluate GEP analysis outside clinical trials...
Autores principales: | Chen, Yan‐Ting, Valent, Erik T., van Beers, Erik H., Kuiper, Rowan, Oliva, Stefania, Haferlach, Torsten, Chng, Wee‐Joo, van Vliet, Martin H., Sonneveld, Pieter, Larocca, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290833/ https://www.ncbi.nlm.nih.gov/pubmed/34448362 http://dx.doi.org/10.1111/ijlh.13691 |
Ejemplares similares
-
Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
por: Ubels, Joske, et al.
Publicado: (2018) -
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile
por: Hofste op Bruinink, Davine, et al.
Publicado: (2022) -
V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
por: Mutsaers, Pim, et al.
Publicado: (2021) -
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020) -
MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)